Stocks-JAZZ-Jazz Pharmaceuticals

JAZZ Jazz Pharmaceuticals

109.70 0.66 (0.61%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Stocks-JAZZ-Jazz Pharmaceuticals
JAZZ Jazz Pharmaceuticals
Trade

Overview

Prev Close 109.70
Day's Range 107.92 - 110.03
52 Week Range 98.86 - 137.06
Average Volume (3M) 680.68K
1-Year Return -13.53%
Beta0.6534
Market Cap 6.77B
P/E Ratio19.6
Revenue3.91B
EPS5.5981
Dividend (Yield) 0 (0%)
Sector
Health Technology
Industry
Pharmaceuticals Major
CEO
Bruce C. Cozadd, MBA
Employees
2,800

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2023: Jazz Pharmaceuticals's revenues increased by 4.78% and amounted to 3.83B. Net income increased by 285.14% to 414.83M. Net assets increased by 21.11% to 3.74B and EPS increased from -3.58 to 6.10.
JAZZ's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
73.60%
Net Profit Margin
5.67%
Operating Margin
16.63%
Return On Investment
2.78%
09/23
12/23
03/24
06/24
Total Revenue
972.14M
1.01B
901.98M
1.02B
Gross Profit
715.1M
753.14M
806.5M
913.92M
Operating Income
172.39M
202.22M
76.21M
199.44M
Net Income
146.82M
94.15M
-14.62M
168.57M